Xponance Inc. Takes Position in Guardant Health, Inc. (NASDAQ:GH)

Xponance Inc. bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,534 shares of the company's stock, valued at approximately $261,000.

Other hedge funds have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in Guardant Health in the fourth quarter valued at approximately $26,000. SBI Securities Co. Ltd. bought a new position in shares of Guardant Health in the fourth quarter valued at $43,000. Kimelman & Baird LLC bought a new position in shares of Guardant Health in the fourth quarter valued at $58,000. Jones Financial Companies Lllp increased its holdings in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock worth $88,000 after acquiring an additional 929 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Guardant Health Price Performance

Guardant Health stock traded up $1.02 during mid-day trading on Wednesday, reaching $43.49. 1,285,125 shares of the company were exchanged, compared to its average volume of 2,142,141. The company has a fifty day simple moving average of $44.65 and a 200-day simple moving average of $34.66. The firm has a market cap of $5.37 billion, a PE ratio of -12.22 and a beta of 1.50. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of analyst reports. Stephens reissued an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. The Goldman Sachs Group lifted their price target on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Barclays initiated coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price objective on the stock. Stifel Nicolaus lifted their target price on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Piper Sandler boosted their target price on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health presently has a consensus rating of "Buy" and an average target price of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.